In­cyte turns to Penn for a col­lab­o­ra­tion on next-gen can­cer com­bos

In­cyte has signed off on a mul­ti-year deal to col­lab­o­rate with sci­en­tists at the Uni­ver­si­ty of Penn­syl­va­nia on its next-gen com­bos and can­cer ther­a­pies.

The uni­ver­si­ty’s Abram­son Can­cer Cen­ter will take a lead role in look­ing at pa­tient se­lec­tion and com­bi­na­tion op­por­tu­ni­ties as In­cyte ad­vances its plans to de­vel­op new and more ef­fec­tive im­munother­a­pies. And they’ll be col­lab­o­rat­ing on a bioin­for­mat­ics pro­gram in clin­i­cal im­munother­a­py.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.